PortfoliosLab logoPortfoliosLab logo
ABT vs. OGN
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ABT vs. OGN - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Abbott Laboratories (ABT) and Organon & Co. (OGN). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ABT achieves a -29.78% return, which is significantly lower than OGN's 87.63% return.


ABT

1D
0.02%
1M
-0.63%
YTD
-29.78%
6M
-29.78%
1Y
-33.61%
3Y*
-3.93%
5Y*
-2.65%
10Y*
10.35%

OGN

1D
0.15%
1M
1.21%
YTD
87.63%
6M
85.05%
1Y
43.20%
3Y*
-8.35%
5Y*
-13.60%
10Y*
*Multi-year figures are annualized to reflect compound growth (CAGR)

ABT vs. OGN - Yearly Performance Comparison


2026 (YTD)20252024202320222021
ABT
Abbott Laboratories
-29.78%12.87%4.81%2.26%-20.68%32.67%
OGN
Organon & Co.
87.63%-50.71%9.92%-45.12%-4.86%-12.15%

Correlation

The correlation between ABT and OGN is 0.15, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.15

Correlation (3Y)
Calculated over the trailing 3-year period

0.24

Correlation (5Y)
Calculated over the trailing 5-year period

0.32

Correlation (All Time)
Calculated using the full available price history since Jun 3, 2021

0.32

The correlation between ABT and OGN shifts across timeframes, from 0.15 (1 year) to 0.32 (all time), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap

ABT:

$151.97B

OGN:

$3.52B

EPS

ABT:

$3.59

OGN:

$0.94

PE Ratio

ABT:

24.24

OGN:

14.22

PS Ratio

ABT:

3.37

OGN:

0.57

PB Ratio

ABT:

2.30

OGN:

3.90K

Total Revenue (TTM)

ABT:

$45.13B

OGN:

$6.16B

Gross Profit (TTM)

ABT:

$25.45B

OGN:

$3.27B

EBITDA (TTM)

ABT:

$10.80B

OGN:

$1.33B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ABT vs. OGN — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

ABT
ABT Risk / Return Rank: 33
Overall Rank
ABT Sharpe Ratio Rank: 11
Sharpe Ratio Rank
ABT Sortino Ratio Rank: 33
Sortino Ratio Rank
ABT Omega Ratio Rank: 33
Omega Ratio Rank
ABT Calmar Ratio Rank: 77
Calmar Ratio Rank
ABT Martin Ratio Rank: 11
Martin Ratio Rank

OGN
OGN Risk / Return Rank: 6262
Overall Rank
OGN Sharpe Ratio Rank: 6262
Sharpe Ratio Rank
OGN Sortino Ratio Rank: 6565
Sortino Ratio Rank
OGN Omega Ratio Rank: 6767
Omega Ratio Rank
OGN Calmar Ratio Rank: 5959
Calmar Ratio Rank
OGN Martin Ratio Rank: 5858
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

ABT vs. OGN - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Abbott Laboratories (ABT) and Organon & Co. (OGN). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


ABTOGNDifference
Sharpe ratioReturn per unit of total volatility

-2.03

Sortino ratioReturn per unit of downside risk

-3.44

Omega ratioGain probability vs. loss probability

0.74

1.21

-0.47

Calmar ratioReturn relative to maximum drawdown

-0.86

0.91

-1.77

Martin ratioReturn relative to average drawdown

-2.00

1.82

-3.82

ABT vs. OGN - Sharpe Ratio Comparison

The current ABT Sharpe Ratio is -1.41, which is lower than the OGN Sharpe Ratio of 0.62. The chart below compares the historical Sharpe Ratios of ABT and OGN, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


ABTOGNDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

-1.41

0.62

-2.03

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

-0.12

-0.28

+0.16

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.44

Sharpe Ratio (All Time)

Calculated using the full available price history

0.49

-0.29

+0.78

Drawdowns

ABT vs. OGN - Drawdown Comparison

The maximum ABT drawdown since its inception was -45.66%, smaller than the maximum OGN drawdown of -82.69%. Use the drawdown chart below to compare losses from any high point for ABT and OGN.


Loading charts...

Drawdown Indicators


ABTOGNDifference

Max Drawdown

Largest peak-to-trough decline

-45.66%

-82.69%

+37.03%

Max Drawdown (1Y)

Largest decline over 1 year

-38.99%

-47.96%

+8.97%

Max Drawdown (3Y)

Largest decline over 3 years

-39.64%

-74.10%

+34.46%

Max Drawdown (5Y)

Largest decline over 5 years

-39.64%

-82.69%

+43.05%

Max Drawdown (10Y)

Largest decline over 10 years

-39.64%

Current Drawdown

Current decline from peak

-36.40%

-59.26%

+22.86%

Average Drawdown

Average peak-to-trough decline

-10.83%

-43.15%

+32.32%

Ulcer Index

Depth and duration of drawdowns from previous peaks

16.86%

23.81%

-6.95%

Volatility

ABT vs. OGN - Volatility Comparison

Abbott Laboratories (ABT) has a higher volatility of 7.34% compared to Organon & Co. (OGN) at 1.33%. This indicates that ABT's price experiences larger fluctuations and is considered to be riskier than OGN based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ABTOGNDifference

Volatility (1M)

Calculated over the trailing 1-month period

7.34%

1.33%

+6.01%

Volatility (6M)

Calculated over the trailing 6-month period

18.93%

52.85%

-33.92%

Volatility (1Y)

Calculated over the trailing 1-year period

23.96%

69.68%

-45.72%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

21.97%

48.81%

-26.84%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

23.63%

48.84%

-25.21%

Dividends

ABT vs. OGN - Dividend Comparison

ABT's dividend yield for the trailing twelve months is around 2.80%, more than OGN's 0.60% yield.


PositionTTM20252024202320222021202020192018201720162015
ABT
Abbott Laboratories
2.80%1.88%1.95%1.85%1.71%1.28%1.32%1.47%1.55%1.86%2.71%2.14%
OGN
Organon & Co.
0.60%4.74%7.51%7.77%4.01%1.84%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

ABT vs. OGN - Financials Comparison

This section allows you to compare key financial metrics between Abbott Laboratories and Organon & Co.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


2.00B4.00B6.00B8.00B10.00B12.00B20222023202420252026
11.16B
1.46B
(ABT) Total Revenue
(OGN) Total Revenue
Values in USD except per share items

ABT vs. OGN - Profitability Comparison

The chart below illustrates the profitability comparison between Abbott Laboratories and Organon & Co. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

50.0%55.0%60.0%65.0%20222023202420252026
56.3%
53.6%
Portfolio components
ABT - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Abbott Laboratories reported a gross profit of 6.28B and revenue of 11.16B. Therefore, the gross margin over that period was 56.3%.

OGN - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Organon & Co. reported a gross profit of 783.00M and revenue of 1.46B. Therefore, the gross margin over that period was 53.6%.

ABT - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Abbott Laboratories reported an operating income of 1.84B and revenue of 11.16B, resulting in an operating margin of 16.5%.

OGN - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Organon & Co. reported an operating income of 266.00M and revenue of 1.46B, resulting in an operating margin of 18.2%.

ABT - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Abbott Laboratories reported a net income of 1.08B and revenue of 11.16B, resulting in a net margin of 9.7%.

OGN - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Organon & Co. reported a net income of 146.00M and revenue of 1.46B, resulting in a net margin of 10.0%.


Frequently Asked Questions


ABT and OGN have a correlation of 0.15, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ABT has higher volatility (7.34%) compared to OGN (1.33%). In terms of maximum drawdown, ABT dropped -45.66% vs OGN's -82.69%.

OGN currently has the higher Sharpe Ratio (0.62 vs -1.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ABT and OGN

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer